Neopterin Dosage in the Eye

Appreciation of the Possibility of Dosing Neopterin in Eye Liquids. Pilot Study of Neopterin Dosage in Eye Liquids.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03497481

Acronym

CHA

Enrollment

Registered

2018-04-13

Start date

2018-06-22

Completion date

2019-01-25

Last updated

2022-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Keywords

eye's anterior chamber fluid, cerebrospinal fluid, inflammatory pathology

Brief summary

The purpose of the study is to determine whether neopterin can be dosed in the fluid of the eye's anterior chamber for patient with non-inflammatory and non-infectious ophthalmic pathology.

Detailed description

The study will be explained to subjects who are about to undergo ophthalmologic surgery. They will sign an informed consent and be included in the study. Urine sample will be collected specifically for the study. Eye's anterior chamber fluid will also be collected during the surgery as it is the usual practice (the sample is used for the neopterin dosage instead of being thrown away). These samples will be centrifuged, frozen in a -80° C freezer. At the end of the study, all the samples will be sent to the central Lab for the neopterin dosage analysis. Results will be communicated to the principal investigator afterward.

Interventions

BIOLOGICALSamples

Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years-old * Non inflammatory or non infectious ophthalmic pathology requiring puncture of eye's anterior chamber fluid. * Minimum of 200 microliter sample * Immunocompetent subjects * Signed and dated informed consent * Samples management in accordance with the pre-analytical conditions specified in the protocol Non-inclusion criteria: * Age \< 18 years-old * Subjects treated with intraocular corticoids, antibiotics or anti-inflammatory, locally or in systemic injection, prior to inclusion.

Exclusion criteria

* Subjects who exercised his right of withdrawal * Study suspended on principal investigator, sponsor or health authorities' demand. * Deceased subjects

Design outcomes

Primary

Measure	Time frame	Description
Detection and dosage of neopterin in the eye	3 month	HCL will detect and dose the neopterin in the eye's anterior chamber fluid

Secondary

Measure	Time frame	Description
Neopterin concentration comparison between study values and reference value.	3 month	The reference values are standards established by the Neurobiology Lab from Lyon CHU which is the central lab that will performed the neopterin dosages.
False positives identification and elimination.	3 month	False positives will be determined by calibration of creatinine dosage in eye and urine samples.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026